Where Does Gifted Education Go From Here: Chaos or Community?
Gifted Child Quarterly · 2022-04 · 66 (2) · 163-168
DOI: 10.1177/00169862211066947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gifted Child Quarterly, online erschienen am 28.12.2021. Verfasst von Scott J. Peters. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
For anyone who puts pen to paper, there can be no greater compliment than when someone reads your work, except when that person then takes the time to think about it and respond. As part of this special issue, almost 50 people took the time to engage on the topic of equity in gifted education and respond to the ideas I offered (see Peters, 2022). It was a gift that left me humbled. Because of the number of commentaries and range of ideas offered, my goal in this final paper was not to respond or react to them individually. Instead, I printed them all out, spread them across the floor of my office, and tried to find areas of agreement that might help the field move forward. As many gifted education scholars and practitioners have long lamented, the existence of disproportional representation within gifted and talented programs has gone on for too long and the time has come for bold, collective action. Although they covered a range of topics, in reading through the commentaries, there appeared to be two broad areas in which most of authors agree:
Zitieren
APA
Peters, S. J. (2022). Where Does Gifted Education Go From Here: Chaos or Community?. Gifted Child Quarterly, 66(2), 163-168. https://doi.org/10.1177/00169862211066947
Vancouver
Peters SJ. Where Does Gifted Education Go From Here: Chaos or Community?. Gifted Child Quarterly. 2022;66(2):163-168. doi:10.1177/00169862211066947
BibTeX
@article{Peters2022,
author = {Peters, Scott J.},
title = {Where Does Gifted Education Go From Here: Chaos or Community?},
journal = {Gifted Child Quarterly},
year = {2022},
volume = {66},
number = {2},
pages = {163--168},
doi = {10.1177/00169862211066947}
}
EUVIMED